BR112022010311A2 - Métodos de tratamento de hipertensão arterial pulmonar - Google Patents
Métodos de tratamento de hipertensão arterial pulmonarInfo
- Publication number
- BR112022010311A2 BR112022010311A2 BR112022010311A BR112022010311A BR112022010311A2 BR 112022010311 A2 BR112022010311 A2 BR 112022010311A2 BR 112022010311 A BR112022010311 A BR 112022010311A BR 112022010311 A BR112022010311 A BR 112022010311A BR 112022010311 A2 BR112022010311 A2 BR 112022010311A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- arterial hypertension
- pulmonary arterial
- treatment
- patient
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962941910P | 2019-11-29 | 2019-11-29 | |
| US202063023452P | 2020-05-12 | 2020-05-12 | |
| US202063076149P | 2020-09-09 | 2020-09-09 | |
| PCT/EP2020/083593 WO2021105331A1 (en) | 2019-11-29 | 2020-11-27 | Methods of treating pulmonary arterial hypertension |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022010311A2 true BR112022010311A2 (pt) | 2022-08-16 |
Family
ID=73726769
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022010311A BR112022010311A2 (pt) | 2019-11-29 | 2020-11-27 | Métodos de tratamento de hipertensão arterial pulmonar |
Country Status (18)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024099953A1 (en) * | 2022-11-07 | 2024-05-16 | Actelion Pharmaceuticals Ltd | Combination of macitentan and tadalafil for the treatment of pulmonary arterial hypertension |
| KR102663470B1 (ko) * | 2023-03-16 | 2024-05-10 | 주식회사 케어사이드 | 폐성 고혈압에 의한 심장 질환 예방 및 심장 치료용 조성물 및 이를 포함하는 기능성 제제 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1693372A1 (en) | 2000-12-18 | 2006-08-23 | Actelion Pharmaceuticals Ltd. | Novel Sulfamides and their use as endothelin receptor antagonists |
| TWI316055B (cg-RX-API-DMAC10.html) | 2001-04-26 | 2009-10-21 | Nippon Shinyaku Co Ltd | |
| US20050101608A1 (en) * | 2003-09-24 | 2005-05-12 | Santel Donald J. | Iloprost in combination therapies for the treatment of pulmonary arterial hypertension |
| ES2393117T3 (es) | 2005-09-12 | 2012-12-18 | Actelion Pharmaceuticals Ltd. | Composición farmacéutica estable que comprende una pirimidina-sulfamida |
| AR062501A1 (es) | 2006-08-29 | 2008-11-12 | Actelion Pharmaceuticals Ltd | Composiciones terapeuticas |
| MX350011B (es) | 2008-08-13 | 2017-08-22 | Actelion Pharmaceuticals Ltd | Composiciones terapeuticas que contienen macitentan. |
| SG176915A1 (en) | 2009-06-26 | 2012-01-30 | Nippon Shinyaku Co Ltd | Crystals |
| WO2011024874A1 (ja) | 2009-08-26 | 2011-03-03 | 日本新薬株式会社 | 塩基付加塩 |
| EA026074B1 (ru) | 2010-10-15 | 2017-02-28 | Джилид Сайэнс, Инк. | Способы, включающие применение композиции амбризентана и тадалафила для лечения легочной артериальной гипертензии |
| CN106461677B (zh) * | 2014-04-22 | 2018-09-11 | 国立大学法人东北大学 | 肺高血压病的检查方法 |
| AU2016207046B2 (en) * | 2015-01-13 | 2021-04-01 | Vivus Llc | Combination therapy for pulmonary hypertension |
| RU2763525C2 (ru) * | 2016-10-27 | 2021-12-30 | Пульмокин, Инк. | Комбинированная терапия для лечения легочной гипертензии |
| EP3897646B1 (en) * | 2018-12-21 | 2024-05-22 | Actelion Pharmaceuticals Ltd | Macitentan for the treatment of pulmonary arterial hypertension |
-
2020
- 2020-11-27 IL IL293271A patent/IL293271A/en unknown
- 2020-11-27 PE PE2022000799A patent/PE20221320A1/es unknown
- 2020-11-27 CA CA3158292A patent/CA3158292A1/en active Pending
- 2020-11-27 ES ES20820054T patent/ES2994089T3/es active Active
- 2020-11-27 CN CN202080081138.2A patent/CN114728002A/zh active Pending
- 2020-11-27 CR CR20220305A patent/CR20220305A/es unknown
- 2020-11-27 EP EP20820054.3A patent/EP4065119B1/en not_active Revoked
- 2020-11-27 PH PH1/2022/551294A patent/PH12022551294A1/en unknown
- 2020-11-27 AU AU2020392424A patent/AU2020392424A1/en not_active Abandoned
- 2020-11-27 JO JOP/2022/0127A patent/JOP20220127A1/ar unknown
- 2020-11-27 US US17/780,064 patent/US12485119B2/en active Active
- 2020-11-27 MX MX2022006403A patent/MX2022006403A/es unknown
- 2020-11-27 WO PCT/EP2020/083593 patent/WO2021105331A1/en not_active Ceased
- 2020-11-27 JP JP2022531531A patent/JP7721520B2/ja active Active
- 2020-11-27 TW TW109141697A patent/TW202133851A/zh unknown
- 2020-11-27 BR BR112022010311A patent/BR112022010311A2/pt not_active IP Right Cessation
- 2020-11-27 KR KR1020227017465A patent/KR20220106974A/ko not_active Ceased
-
2022
- 2022-06-28 EC ECSENADI202251163A patent/ECSP22051163A/es unknown
-
2024
- 2024-07-24 JP JP2024118344A patent/JP7620758B2/ja active Active
-
2025
- 2025-07-30 JP JP2025127467A patent/JP2025172745A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ECSP22051163A (es) | 2022-07-29 |
| JOP20220127A1 (ar) | 2023-01-30 |
| CR20220305A (es) | 2022-07-28 |
| EP4065119B1 (en) | 2024-09-04 |
| JP7721520B2 (ja) | 2025-08-12 |
| PH12022551294A1 (en) | 2023-11-20 |
| TW202133851A (zh) | 2021-09-16 |
| US12485119B2 (en) | 2025-12-02 |
| JP7620758B2 (ja) | 2025-01-23 |
| JP2024153734A (ja) | 2024-10-29 |
| CA3158292A1 (en) | 2021-06-03 |
| CN114728002A (zh) | 2022-07-08 |
| KR20220106974A (ko) | 2022-08-01 |
| IL293271A (en) | 2022-07-01 |
| EP4065119A1 (en) | 2022-10-05 |
| JP2023504115A (ja) | 2023-02-01 |
| US20230032813A1 (en) | 2023-02-02 |
| WO2021105331A1 (en) | 2021-06-03 |
| AU2020392424A1 (en) | 2022-06-02 |
| JP2025172745A (ja) | 2025-11-26 |
| ES2994089T3 (en) | 2025-01-17 |
| PE20221320A1 (es) | 2022-09-08 |
| MX2022006403A (es) | 2022-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019001674A1 (es) | Inhibidores de imidazopirazina de tirosina quinasa de bruton. | |
| CY1126537T1 (el) | Αναστολεις prmt5 | |
| JOP20200222A1 (ar) | أشكال كريستالين لمثبط أنزيم كيناز تيروسين بروتون | |
| CY1126152T1 (el) | Ενωσεις-αναστολεις της rip1 και μεθοδοι παρασκευης και χρησης αυτων | |
| JOP20220200A1 (ar) | مركبات عالية النشاط ضد covid-19 | |
| MX2021005011A (es) | Métodos de tratamiento del cáncer en pacientes identificados por biomarcadores con inhibidores no covalentes de cinasa 7 dependiente de ciclina (cdk7). | |
| CO2019005236A2 (es) | Métodos para tratar afecciones inflamatorias | |
| CL2022001743A1 (es) | Dosis de gamma-hidroxibutirato (ghb) | |
| MX2023014059A (es) | Terapeuticos para la degradacion de una proteina quiinasa de serina/ treonina mutante. | |
| BR112015001419A8 (pt) | composto, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo | |
| JOP20220056A1 (ar) | مركبات rip1 تثبيطية وطرق عملها واستخدامها | |
| ECSP20024210A (es) | Uso de inhibidores de p38 para reducir la expresión de dux4 | |
| BRPI1011838B8 (pt) | compostos de carboxamida heterocíclica de diamino, seu uso, composição farmacêutica que os compreende e inibidor contra a atividade de cinase de proteína de fusão eml4-alk | |
| UY31017A1 (es) | Uso de un inhibidor del factor &(alfa) de necrosis tumoral mas un antihistaminico para el tratamiento de la rinitis alérgica y la conjuntivitis alérgica. | |
| BR112021021826A8 (pt) | Uso de apremilaste e um inibidor da tirosina quinase 2 no tratamento de uma doença ou um transtorno responsivo à inibição da fosfodiesterase tipo 4 | |
| MX2017014645A (es) | Profarmacos de alvocidib que tienen una biodisponibilidad aumentada. | |
| MX2023000812A (es) | Analogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton. | |
| AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
| BR112015026021A2 (pt) | terapia de combinação compreendendo um inibidor de tor quinase e n-(3-(5-flúor-2-(4-(2-met-oxietoxi)fenilamino)pirimidin-4-ilamino)fenil)acrilamida para o tratamento de câncer | |
| BR112015026247A2 (pt) | métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor | |
| BR112016028446A2 (pt) | inibidor de complemento de ornithodoros moubata para uso no tratamento de doenças mediadas por complemento em pacientes com polimorfismo de c5 | |
| CR20220280A (es) | Terapia de combinación que comprende un inhibidor de alk2 y un inhibidor de jak2 | |
| PE20210096A1 (es) | Inhibidor de ret para uso en tratar cancer que tiene una alteracion de ret | |
| TW201613577A (en) | Pharmaceutical combinations | |
| BR112016029067A2 (pt) | ?composto, composição farmacêutica, e, métodos para inibir o canal de potássio medular externo renal, para causar diurese, natriurese ou ambas e para tratar um ou mais distúrbios? |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2856 DE 30-09-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |